Alpha Cognition Inc
ACOG
Pozycja w akcjach
#20187
Alpha Cognition Inc., a biopharmaceutical company, engages in the development... Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
Cena akcji
$8.47
Ostatnia synchronizacja: 2026-10-19
Kapitalizacja rynkowa
$131.47M
Zmiana (1 dzień)
3.36%
Zmiana (1 rok)
68.29%
Kraj
US
Handel Alpha Cognition Inc (ACOG)
Kategoria
Healthcare
Zyski dla Alpha Cognition Inc (ACOG)
Zyski w Jun 2026 TTM: 0.00
Według najnowszych raportów finansowych Alpha Cognition Inc, obecny zysk firmy wynosi 0.00. W roku 2022 firma osiągnęła zysk w wysokości $-12.11M, wzrost w porównaniu do zysku z roku 2021, który wynosił $-19.55M. Wyświetlany zysk to zysk przed odsetkami i podatkami, czyli EBIT.
Historia zysków firmy Alpha Cognition Inc od 2018 do 2026
Zyski na koniec każdego roku
| Rok | Zyski | Zmień |
|---|---|---|
| 2026 (TTM) | 0.00 | -100.00% |
| 2023 | $-13.77M | 13.68% |
| 2022 | $-12.11M | -38.02% |
| 2021 | $-19.55M | 237.90% |
| 2020 | $-5.78M | -12.45% |
| 2019 | $-6.61M | 20,254.71% |
| 2018 | $-32.46K | 0.00% |
Zyski podobnych firm lub konkurentów
| Firma | Zyski | Różnica w zyskach | Kraj |
|---|---|---|---|
| $5.27B | - |
US
|
|
| $-3.09B | - |
US
|
|
| $-4.02B | - |
AU
|
|
| - | - |
CH
|
|
| $1.95B | - |
NL
|
